▶ 調査レポート

血漿タンパク質治療薬の世界市場分析・規模・シェア・成長・動向・予測:製品別(凝固因子、免疫グロブリン、アルブミン、C1-エステラーゼインヒビター、アルファ-1プロテイナーゼインヒビター、高度免疫グロブリン)、用途別(血友病、原発性免疫不全症、特発性血小板減少性紫斑病、二次免疫不全症、遺伝性血管性浮腫、川崎病、GBS、CIDP)

• 英文タイトル:Plasma Protein Therapeutics Market (Product - Coagulation Factors, Immunoglobulins, Albumins, C1-esterase Inhibitors, and Alpha-1 Proteinase Inhibitors and Hyperimmune Globulins; Application - Hemophilia, Primary Immunodeficiency Disorder, Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency (CLL, Multiple Myeloma, and Congenital AIDS), and Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024

Transparency Market Researchが調査・発行した産業分析レポートです。血漿タンパク質治療薬の世界市場分析・規模・シェア・成長・動向・予測:製品別(凝固因子、免疫グロブリン、アルブミン、C1-エステラーゼインヒビター、アルファ-1プロテイナーゼインヒビター、高度免疫グロブリン)、用途別(血友病、原発性免疫不全症、特発性血小板減少性紫斑病、二次免疫不全症、遺伝性血管性浮腫、川崎病、GBS、CIDP) / Plasma Protein Therapeutics Market (Product - Coagulation Factors, Immunoglobulins, Albumins, C1-esterase Inhibitors, and Alpha-1 Proteinase Inhibitors and Hyperimmune Globulins; Application - Hemophilia, Primary Immunodeficiency Disorder, Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency (CLL, Multiple Myeloma, and Congenital AIDS), and Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024 / TPM-B05020資料のイメージです。• レポートコード:TPM-B05020
• 出版社/出版日:Transparency Market Research / 2018年5月10日
• レポート形態:英文、PDF、144ページ
• 納品方法:Eメール
• 産業分類:Pharmaceutical
• 販売価格(消費税別)
  Single User¥857,660 (USD5,795)▷ お問い合わせ
  Multi User¥1,301,660 (USD8,795)▷ お問い合わせ
  Global Site License¥1,745,660 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、血漿タンパク質治療薬の世界市場について調べ、血漿タンパク質治療薬の世界規模、市場動向、市場環境、製品別(凝固因子、免疫グロブリン、アルブミン、C1-エステラーゼインヒビター、アルファ-1プロテイナーゼインヒビター、高度免疫グロブリン)分析、用途別(血友病、原発性免疫不全症、特発性血小板減少性紫斑病、二次免疫不全症、遺伝性血管性浮腫、川崎病、GBS、CIDP)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。
・序文・調査範囲・調査手法
・エグゼクティブサマリー
・血漿タンパク質治療薬の世界市場動向
・血漿タンパク質治療薬の世界市場環境
・血漿タンパク質治療薬の世界市場規模
・血漿タンパク質治療薬の世界市場規模:製品別(凝固因子、免疫グロブリン、アルブミン、C1-エステラーゼインヒビター、アルファ-1プロテイナーゼインヒビター、高度免疫グロブリン)
・血漿タンパク質治療薬の世界市場規模:用途別(血友病、原発性免疫不全症、特発性血小板減少性紫斑病、二次免疫不全症、遺伝性血管性浮腫、川崎病、GBS、CIDP)
・血漿タンパク質治療薬の世界市場:地域別市場規模・分析
・血漿タンパク質治療薬の北米市場規模・予測
・血漿タンパク質治療薬のアメリカ市場規模・予測
・血漿タンパク質治療薬の中南米市場規模・予測
・血漿タンパク質治療薬のヨーロッパ市場規模・予測
・血漿タンパク質治療薬のアジア市場規模・予測
・血漿タンパク質治療薬の中国市場規模・予測
・競争状況・関連企業情報

Global Plasma Protein Therapeutics Market: Overview

Transparency Market Research’s new report on the global plasma protein therapeutics market presents detailed insights into growth of the market for the 2017-2024 forecast timeframe. The growth analysis of this market for the aforementioned forecast period is presented based on past and current growth scenario. The report comprises a detailed executive summary, wherein a market snapshot provides information on various segments and sub-segments. Included in this section is valuable insights into leading segments in terms of product type, application, and geography. The report presents revenue projections of leading segments in terms of US$ Mn.

The market overview section provides qualitative analysis of the overall plasma protein therapeutics market, which looks into growth indicators and factors governing this market through 2024. In addition, market attractiveness analysis based on growth in key regional markets and competitive outlook of the plasma protein therapeutics market are a highlight of this section. The competitive hierarchy has been evaluated based on market share analysis of companies in the plasma protein therapeutics market. Insights into competitive landscape will help existing as well as new participants to formulate lucrative strategies to establish in this market.

Global Plasma Protein Therapeutics Market: Research Methodology

The report is a result of a meticulous primary and secondary research phase. Primary research constitute major part of research efforts wherein analysts reached out to industry experts and opinion leaders for insights on the growth of plasma protein therapeutics market. Analysts conducted face to face interviews, telephonic interviews along with e-mail interactions to reach out to industry experts. Participants reached out in the primary research phase typically include biologists, academicians, researchers, and medical personnel.

Secondary research comprised study of company websites, press releases, relevant business documents, annual reports, and various national and internal databases. Science journals, industry publications, trade publications, technical literature, and webcasts specific to companies were some other secondary sources reached out for the study. The extensive secondary research phase helped evaluate market size, top products, top industry players, industry associations, etc.

Following primary and secondary research, data triangulation method along with inputs from in-house experts validated the growth analysis of plasma protein therapeutics market. Using MS-Excel, data was sorted to further aid determine the growth chart of plasma protein therapeutics market. Finally, insights obtained from industry experts and information scrutinized were collated in PDF format.

Global Plasma Protein Therapeutics Market: Competitive Outlook

Included in the report is a competitive dashboard of the plasma protein therapeutics market. It identifies leading players operating in the plasma protein therapeutics market along with an elaborate competitive profile of each of them. Technological advancements, product portfolio, business strategy, and financials are some of the parameters based on which key players in the plasma protein therapeutics market have been profiled. An analysis of strength, weakness, threat, and opportunities of key players through 2024 is a highlight of this report.

レポート目次

Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology

Chapter 2 Executive Summary
2.1 Global Plasma Protein Therapeutics Market Snapshot

Chapter 3 Global Plasma Protein Therapeutics Market Revenue Analysis, 2014–2024 (US$ Mn)
3.1 Introduction
3.2 Regulatory Scenario
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Restraints
3.3.3 Opportunity
3.4 Market Attractiveness Analysis, by Region, 2015
3.5 Porter’s Five Forces Analysis
3.6 Global Plasma Protein Therapeutics Market Revenue Analysis, By Product Type, 2014–2024 (US$ Mn)
3.6.1 Global Immunoglobulins Market Revenue, 2014–2024 (US$ Mn)
3.6.2 Global Albumin Market Revenue, 2014–2024 (US$ Mn)
3.6.3 Global Coagulation Factors Market Revenue, 2014–2024 (US$ Mn)
3.6.4 Global C1-esterase Inhibitors Market Revenue, 2014–2024 (US$ Mn)
3.6.5 Others (e.g. Alpha-1 Proteinase Inhibitors, Hyperimmune Globulins)
3.7 Global Plasma Protein Therapeutics Market Analysis, By Application, 2014–2024 (US$ Mn)
3.7.1 Global Hemophilia Market Revenue, 2014–2024 (US$ Mn)
3.7.2 Global Primary Immunodeficiency Disorder (PID) Market Revenue, 2014–2024 (US$ Mn)
3.7.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2014–2024 (US$ Mn)
3.7.4 Global Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, Congenital AIDS, etc.) Market Revenue, 2014–2024 (US$ Mn)
3.7.5 Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
3.8 Competitive Landscape
3.8.1 Market Positioning of Key Players, 2015
3.8.2 Recommendations
3.9 Pipeline Analysis
3.9.1 Phase 1 and Phase 2 Drugs (Qualitative Analyses)
3.9.2 Phase 3 and Phase 4 Drugs (Quantitative), Forecasts till 2024

Chapter 4 North America Plasma Protein Therapeutics Market Revenue Analysis, 2014–2024 (US$ Mn)
4.1 North America Plasma Protein Therapeutics Market Revenue, By Product Type, 2014–2024 (US$ Mn)
4.1.1 North America Immunoglobulins Market Revenue, 2014–2024 (US$ Mn)
4.1.2 North America Albumin Market Revenue, 2014–2024 (US$ Mn)
4.1.3 North America Coagulation Factors Market Revenue, 2014–2024 (US$ Mn)
4.1.4 North America C1-esterase Inhibitors Market Revenue, 2014–2024 (US$ Mn)
4.1.5 Others
4.2 North America Plasma Protein Therapeutics Market Revenue, By Application, 2014–2024 (US$ Mn)
4.2.1 North America Hemophilia Market Revenue, 2014–2024 (US$ Mn)
4.2.2 North America Primary Immunodeficiency Disorder (PID) Market Revenue, 2014–2024 (US$ Mn)
4.2.3 North America Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2014–2024 (US$ Mn)
4.2.4 North America Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, and Congenital AIDS, etc.) Market Revenue, 2014–2024 (US$ Mn)
4.2.5 Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
4.3 North America Plasma Protein Therapeutics Market Revenue, by Country 2014–2024 (US$ Mn)

Chapter 5 Europe Plasma Protein Therapeutics Market Revenue, 2014–2024 US$ Mn)
5.1 Europe Plasma Protein Therapeutics Market Revenue, By Product Type, 2014–2024 (US$ Mn)
5.1.1 Europe Immunoglobulins Market Revenue, 2014–2024 (US$ Mn)
5.1.2 Europe Albumin Market Revenue, 2014–2024 (US$ Mn)
5.1.3 Europe Coagulation Factors Market Revenue, 2014–2024 (US$ Mn)
5.1.4 Europe C1-esterase Inhibitors Market Revenue, 2014–2024 (US$ Mn)
5.1.5 Others
5.2 Europe Plasma Protein Therapeutics Market Revenue, By Application, 2014–2024 (US$ Mn)
5.2.1 Europe Hemophilia Market Revenue, 2014–2024 (US$ Mn)
5.2.2 Europe Primary Immunodeficiency Disorder (PID) Market Revenue, 2014–2024 (US$ Mn)
5.2.3 Europe Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2014–2024 (US$ Mn)
5.2.4 Europe Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, Congenital AIDS, etc.) Market Revenue, 2014–2024 (US$ Mn)
5.2.5 Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
5.3 Europe Plasma Protein Therapeutics Market Revenue, by Country, 2014–2024 (US$ Mn)

Chapter 6 Asia Pacific Plasma Protein Therapeutics Market Revenue Analysis, 2014–2024 (US$ Mn)
6.1 Asia Pacific Plasma Protein Therapeutics Market Revenue, By Product Type, 2014–2024 (US$ Mn)
6.1.1 Asia Pacific Immunoglobulins Market Revenue, 2014–2024 (US$ Mn)
6.1.2 Asia Pacific Albumin Market Revenue, 2014–2024 (US$ Mn)
6.1.3 Asia Pacific Coagulation Factors Market Revenue, 2014–2024 (US$ Mn)
6.1.4 Asia Pacific C1-esterase inhibitors Market Revenue, 2014–2024 (US$ Mn)
6.1.5 Others
6.2 Asia Pacific Plasma Protein Therapeutics Market Revenue, By Application, 2014–2024 (US$ Mn)
6.2.1 Asia Pacific Hemophilia Market Revenue, 2014–2024 (US$ Mn)
6.2.2 Asia Pacific Primary Immunodeficiency Disorder (PID) Market Revenue, 2014–2024 (US$ Mn)
6.2.3 Asia Pacific Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2014–2024 (US$ Mn)
6.2.4 Asia Pacific Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, and Congenital AIDS, etc.) Market Revenue, 2014–2024 (US$ Mn)
6.2.5 Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
6.3 Asia Pacific Plasma Protein Therapeutics Market by Geography, Market Revenue, 2014–2024 (US$ Mn)

Chapter 7 Latin America Plasma Protein Therapeutics Revenue Analysis, 2014–2024 (US$ Mn)
7.1 Latin America Plasma Protein Therapeutics Market Revenue Analysis, By Product Type, 2014–2024 (US$ Mn)
7.1.1 Latin America Immunoglobulins Market Revenue, 2014–2024 (US$ Mn)
7.1.2 Latin America Albumin Market Revenue, 2014–2024 (US$ Mn)
7.1.3 Latin America Coagulation Factors Market Revenue, 2014–2024 (US$ Mn)
7.1.4 Latin America C1-esterase Inhibitors Market Revenue, 2014–2024 (US$ Mn)
7.1.5 Others
7.2 Latin America Plasma Protein Therapeutics Market Revenue, By Application, 2014–2024 (US$ Mn)
7.2.1 Latin America Hemophilia Market Revenue, 2014–2024 (US$ Mn)
7.2.2 Latin America Primary Immunodeficiency Disorder (PID) Market Revenue, 2014–2024 (US$ Mn)
7.2.3 Latin America Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, 2014–2024 (US$ Mn)
7.2.4 Latin America Secondary Immunodeficiency (e.g. CLL, Multiple Myeloma, and Congenital AIDS, etc.) Market Revenue, 2014–2024 (US$ Mn)
7.2.5 Others (e.g. Hereditary Angioedema, Kawasaki Disease, GBS, and CIDP, etc.)
7.3 Latin America Plasma Protein Therapeutics Market by Geography, Market Revenue, 2014–2024 (US$ Mn)

Chapter 8 Rest of the World (RoW) Plasma Protein Therapeutics Market Revenue Analysis, 2014–2024 (US$ Mn)
8.1 Rest of World Plasma Protein Therapeutics Market Revenue Analysis, By Product Type, 2014–2024 (US$ Mn)
8.2 Rest of World Plasma Protein Therapeutics Market Revenue, By Application, 2014–2024 (US$ Mn)

Chapter 9 Company Profiles
9.1 Baxter International
9.1.1 Company Overview
9.1.2 Product Portfolio
9.1.3 Financial Overview
9.1.4 Business Strategies
9.1.5 Recent Development
9.2 Biotest
9.2.1 Company Overview
9.2.2 Product Portfolio
9.2.3 Financial Overview
9.2.4 Recent Development
9.3 CSL Behring
9.3.1 Company Overview
9.3.2 Product Portfolio
9.3.3 Financial Overview
9.3.4 Business Strategies
9.3.5 Recent Development
9.4 China Biologics
9.4.1 Company Overview
9.4.2 Product Portfolio
9.4.3 Financial Overview
9.4.4 Business Strategies
9.4.5 Recent Development
9.5 GRIFOLS, S.A.
9.5.1 Company Overview
9.5.2 Product Portfolio
9.5.3 Financial Overview
9.5.4 Business Strategies
9.5.5 Recent Development
9.6 Kedrion
9.6.1 Company Overview
9.6.2 Product Portfolio
9.6.3 Financial Overview
9.6.4 Recent Development
9.7 Octapharma USA, Inc.
9.7.1 Company Overview
9.7.2 Product Portfolio
9.7.3 Financial Overview
9.7.4 Recent Development
9.8 Shire Plc.
9.8.1 Company Overview
9.8.2 Product Portfolio
9.8.3 Financial Overview
9.8.4 Business Strategies
9.8.5 Recent Development

List of Tables

Table 1. Plasma Protein Therapeutics Market Snapshot
Table 2. Global Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2014–2024
Table 3. Global Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2014–2024
Table 4. Global Plasma Protein Therapeutics Market Revenue, by Region, (US$ Mn), 2014–2024
Table 5. Pipeline Analysis (Phase I and Phase II)
Table 6. Pipeline Analysis (Phase III): Plasma protein Therapeutics, Expected Launch date of Approval to 2024 (US$ Mn)
Table 7. North America Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2014–2024
Table 8. North America Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2014–2024
Table 9. North America Plasma Protein Therapeutics Market Revenue, by Countries, (US$ Mn), 2014–2024
Table 10. Europe Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2014–2024
Table 11. Europe Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2014–2024
Table 12. Europe Plasma Protein Therapeutics Market Revenue, by Countries, (US$ Mn), 2014–2024
Table 13. Asia Pacific Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2014–2024
Table 14. Asia Pacific Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2014–2024
Table 15. Asia Pacific Plasma Protein Therapeutics Market Revenue by Countries, (US$ Mn), 2014–2024
Table 16. LATAM Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2014–2024
Table 17. LATAM Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2014–2024
Table 18. Latin America Plasma Protein Therapeutics Market Revenue, by Countries, (US$ Mn), 2014–2024
Table 19. ROW Plasma Protein Therapeutics Market Revenue, by Product Type, (US$ Mn), 2014–2024
Table 20. ROW Plasma Protein Therapeutics Market Revenue, by Application, (US$ Mn), 2014–2024